Global Reemergence of Tuberculosis: Are Host Defense Peptides an Option to Ameliorate Disease Burden?

Citation

Flores-Valdez, M. A., & Chopra, S. (2010). Global reemergence of tuberculosis: are host defense peptides an option to ameliorate disease burden?. Microbial Drug Resistance, 16(1), 1-7.

Abstract

Tuberculosis is the most relevant infectious disease worldwide according to the estimates of the World Health Organization, and despite being a curable disease, it requires a 6–9-month therapy with multiple antibiotics. Intermittent drug therapy due to noncompliance or poor delivery of therapy promotes the emergence of bacterial strains showing resistance to multiple drugs and the rise of extremely drug-resistant strains. Moreover, increased antibiotic resistance has been observed for several microorganisms, including extremely drug-resistant tuberculosis, vancomycin-resistant Enterococcus faecalis, or methicillin-resistant Staphylococcus aureusIn vitro, cathelicidin induction results in enhanced mycobacterial clearance, and synthetic human neutrophil peptides had a rather modest bactericidal effect in Mycobacterium tuberculosis-infected mice. In vivo therapeutic efficacy of improved molecules that show enhanced bactericidal action in vitro remains to be tested.


Read more from SRI

  • Banner and attendees at the IEEE Hard Tech Venture Summit

    Cultivating hard tech startups that scale

    IEEE’s Hard Tech Venture Summit convened innovators at SRI to refine strategies and build new networks.

  • Patient going into a MRI

    Bringing surgical tools inside the MRI

    Drawing on SRI’s unique innovation ecosystem, the startup Medical Devices Corner is seeking to improve cancer surgery by advancing MRI-safe teleoperation.

  • Christopher Mims and Susan Patrick

    PARC Forum: How to AI

    The Wall Street Journal tech columnist Christopher Mims and SRI Education’s Susan Patrick discuss how AI can strengthen human agency.